What are the indications for this product?

It is indicated for the treatment of light or moderate pain, as an auxiliary for moderate or severe pain, and for fever abatement.

What is the physical appearance of the product?

The product is a colorless clear or nearly colorless liquid.

Does the company have international certifications?

Yes, the company organizes production in strict accordance with GMP requirements.

Paracetamol Injection 100ml: 1g Glass Bottle

Name: Paracetamol Injection 100ml: 1g Glass Bottle
Brand: Shijiazhuang No. 4 Pharmaceutical Co., Ltd.
SKU: 2054139902

Hebei, ChinaShijiazhuang No. 4 Pharmaceutical Co., Ltd.

US$0.30-0.35

10,000 Pieces

Sample price:US$0.50/piece.Request sample

Product profile

Customization

Available

Application

Internal Medicine

Usage Mode

Infusion

Model NO.

100ml

Suitable for

Adult

State

Liquid

Shape

Infusion

Type

Inorganic Chemicals

Pharmaceutical Technology

Chemical Synthesis

Transport Package

Carton

Specification

100ml glass bottle

Trademark

SHIMEN

Origin

China

HS Code

3004909099

Production Capacity

1000000

Key features

Clear Liquid Formulation: Colorless clear or nearly colorless liquid for easy visual inspection.

Versatile Pain Management: Treats light to moderate pain and serves as an auxiliary for severe pain.

Fever Reduction: Effective treatment for fever abatement in adults and children.

Flexible Dosing Schedule: Recommended every 4 or 6 hours based on weight and age requirements.

GMP Compliant Production: Manufactured in strict accordance with GMP requirements for quality assurance.

Advanced Automation: Full automation control in production and logistics processes.

Global Market Reach: Exported to over 80 countries across Asia, Americas, Europe, Africa, and Oceania.

Established Manufacturer: Leading manufacturer with a 70-year business history in Chinese pharmaceuticals.

Company profile

Shijiazhuang No. 4 Pharmaceutical Co., Ltd.

Hebei, China

Business Type: Manufacturer/FactoryExport Year: 2002-01-01Nearest Port: Tianjin Xingang, Qingdao, ShanghaiAverage Response Time: ≤24hTerms of Payment: LC, T/TInternational Commercial Terms(Incoterms): FOB, CFR, CIF, CIP, EXW

AI-Powered supplier vetting

SummaryShijiazhuang No. 4 Pharmaceutical Co., Ltd. is identified as a Chinese public pharmaceutical manufacturer based in Hebei, with products spanning infusion solutions, injections, tablets, capsules, inhalation products, and other medical materials. The supplier reports ISO 9001, ISO 14001, and GMP certifications, more than ten production lines, automated and information-based production and logistics processes, and substantial stated output across several dosage forms. Its export activity began in 2002, although exports represent only 1%–10% of total sales. The company describes integrated R&D, manufacturing, and marketing capabilities, but the provided information does not establish specific after-sales programs, customization services, or named customer cases. Financial strength cannot be assessed because financial data is excluded.

Supplier typeThe supplier is explicitly classified as a Manufacturer/Factory and is described as an integrated pharmaceutical enterprise covering R&D, industrial production, and marketing. Its listed business covers health and medicine products, including injections, infusion solutions, tablets, capsules, and related dosage forms.

CertificationsThe supplier reports ISO 9001, ISO 14001, and GMP certifications. It also states that production is organized strictly according to GMP requirements, providing explicit evidence of formal quality, environmental, and pharmaceutical manufacturing systems.

R&D capabilityThe supplier describes an integrated R&D, production, and marketing model, reports 50 R&D engineers, and states that its production lines integrate leading equipment and technology at an international advanced level. This supports established technical and development capability, although no specific patents, new-product results, or R&D investment details are provided.

Production capacityProduction capability is strongly supported by more than ten production lines, automated and information-based production and logistics processes, and stated annual outputs of 1.5 billion large-volume injection units and 1 billion units each for tablets, capsules, and small-volume injections. The company also reports more than ten international advanced infusion-solution lines and exports through both agency and self-operated channels.